ESMO 2024 | TACITO: fecal microbiota transplantation with axitinib and pembrolizumab in mRCC
Chiara Ciccarese, MD, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, explores findings from the Phase II TACITO trial (NCT04758507) of fecal microbiota transplantation (FMT) with axitinib and pembrolizumab in metastatic renal cell carcinoma (mRCC). Results showed a significantly higher 1-year progression-free survival and improved objective response rate in the FMT group, with an acceptable safety profile. Median progression-free survival was longer with FMT, indicating potential benefits of microbiota modulation in augmenting checkpoint inhibitor-based therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
